Q&A: Drug payments updated for April
APCs Insider, April 10, 2015
Want to receive articles like this one in your inbox? Subscribe to APCs Insider!
Q: Did CMS make any changes to drug payments for April?
A: CMS updated Addendum B with new payment information based on the updated average sales price information available. The updated rates are published in Addendum B; these items have an asterisk in the column titled “Indicates a change.”
CMS also granted pass-through status (status indicator G) to six new HCPCS codes representing drugs and biologicals beginning April 1:
- C9445, injection, C1 esterase inhibitor (recombinant), Ruconest®, 10 units
- C9448, netupitant, 300 mg, and palonesetron, 0.5mg, oral
- C9449, injection, blinatumomab, 1 mcg
- C9450, injection, fluocinolone acetonide intravitreal implant, 0.01 mg
- C9451, injection, peramivir, 1 mg
- C9452, injection, ceftolozane, 50 mg, and tazobactam, 25 mg
In Transmittal 3217, CMS provides further information regarding C9450. This code is associated with Iluvien® and no other fluocinolone acetonide intravitreal implant. In addition, each implant dose is 0.19 mg, so hospitals should report 19 units of C9450 for each implant.
Editor’s note: Denise Williams, RN, CPC-H, seniorvice president of revenue integrity services at Health Revenue Assurance Associates, Inc., in Fort Lauderdale, Florida, answered this question.
Want to receive articles like this one in your inbox? Subscribe to APCs Insider!
Related Products
Most Popular
- Articles
-
- Don't forget the three checks in medication administration
- Nursing responsibilities for managing pain
- Complications from immobility by body system
- Q&A: Primary, principal, and secondary diagnoses
- The consequences of an incomplete medical record
- Note similarities and differences between HCPCS, CPT® codes
- Practice the six rights of medication administration
- Neurological checks for head injuries
- Skills of effective case managers
- 10 Tips for Educating Elderly Patients
- E-mailed
- Searched